Digest Network Come funziona
Network
/
Società
Ni
Non verificato

Nimbus Therapeutics, LLC

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

11 comunicati stampa

Guarda tutti i comunicati
13/10/2026
Tecnica
Scienza
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Nimbus Therapeutics Strengthens Leadership Team to Support Next Phase of Growth
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
16/04/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026™
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
17/02/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Industria
Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO)
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
06/01/2026
Mercato del lavoro
Industria
Scienza
Fitness
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
19/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
25/04/2025
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
07/03/2025
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
25/02/2025
Oncologia
Salute
Farmaceutica
Cardiologia
Biotecnologia
Mercato del lavoro
Industria
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0
23/10/2024
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Fonte
Nimbus Therapeutics, LLC
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0